APA (7th ed.) Citation

Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, & Huan Li. (2022). Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, and Huan Li. Cost-effectiveness of Nivolumab Plus Ipilimumab as First-line Treatment for American Patients with Unresectable Malignant Pleural Mesothelioma. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Zhuo-miao Ye, et al. Cost-effectiveness of Nivolumab Plus Ipilimumab as First-line Treatment for American Patients with Unresectable Malignant Pleural Mesothelioma. Frontiers Media S.A., 2022.